


 Cite this: *RSC Adv.*, 2022, 12, 34176

Dual activity inhibition of threonine aspartase 1 by a single bisphosphate ligand†

 Alexander Höing, ^a Robin Struth, ^b Christine Beuck, ^c
 Neda Rafieiohosseini, ^d Daniel Hoffmann, ^d Roland H. Stauber, ^e
 Peter Bayer, ^c Jochen Niemeyer ^{*b} and Shirley K. Knauer ^{*a}

Therapy resistance remains a challenge for the clinics. Here, dual-active chemicals that simultaneously inhibit independent functions in disease-relevant proteins are desired though highly challenging. As a model, we here addressed the unique protease threonine aspartase 1, involved in various cancers. We hypothesized that targeting basic residues in its bipartite nuclear localization signal (NLS) by precise bisphosphate ligands inhibits additional steps required for protease activity. We report the bisphosphate anionic bivalent inhibitor **11d**, selectively binding to the basic NLS cluster (²²⁰KRR²²³) with high affinity ($K_D = 300$ nM), thereby disrupting its interaction and function with Importin α ($IC_{50} = 6$ μ M). Cell-free assays revealed that **11d** additionally affected the protease's catalytic substrate *trans*-cleavage activity. Importantly, functional assays comprehensively demonstrated that **11d** inhibited threonine aspartase 1 also in living tumor cells. We demonstrate for the first time that intracellular interference with independent key functions in a disease-relevant protein by an inhibitor binding to a single site is possible.

Received 23rd September 2022

Accepted 23rd November 2022

DOI: 10.1039/d2ra06019a

rsc.li/rsc-advances

Introduction

'Hit once better hit twice!' this saying from the clinical bedside is accepted when treating viral (e.g., COVID) or bacterial infections as well as live threatening diseases, such as cancer.^{1–3} Hence, combination therapies are practiced to improve treatment success and minimize the complications of therapy resistances.^{1–3} Thus, modern chemistry in basic and applied research seeks to expand our treatment repertoire by investigating chemical structures that target multiple independent functions in disease relevant proteins, ideally by a single inhibitor.^{2,3} So far, compounds affecting multiple (unrelated) proteins by 'off target' effects or inhibiting protein function by binding to different sites as well as hybrid drugs combining pharmacophores simultaneously targeting various protein

functions have been explored.^{2,4–7} The concept of 'two for the price of one' is clearly under intense investigation.⁸ For example, it has been shown that inhibiting two different enzymes in inflammatory pathways with a single peptide reduced inflammation.⁹ However, proven examples of molecules effectively targeting independent functions in proteins by binding to a single site not only *in vitro* but also *in vivo* are to the best of our knowledge missing to date.

To thus expand the repertoire of such dual-active compounds, a *trans*-approach combining synthetic and analytical chemistry with a profound knowledge of disease-relevant molecular structures and functions is obligatory. Moreover, as shown by others and us, rational chemical design strategies now allow to precisely target and selectively inhibit small, functionally pivotal protein domains.^{10–12} Based on our previous work,^{13–20} we here choose the cancer-relevant protease threonine aspartase 1 (Taspase 1) as a model for the development of dual active inhibitors for following reasons: For one, proteases are central for life and protease deregulation is associated with a variety of diseases.^{21,22} As shown by others and us, Taspase 1 is not only critically involved in the regulation of cellular development but also in hematological malignancies and solid tumors.^{15,23,24}

Although it belongs to the group of threonine proteases, Taspase 1 is a unique enzyme. In contrast to the exclusively *cis*-active type 2 asparaginases, only Taspase 1 is also able to cleave other substrates in *trans* by hydrolyzing its target proteins at conserved Q³[FILV]²D¹↓G¹X²/D³/D⁴ motifs.^{18,25–27} Thus, the discovery of Taspase 1 founded a new class of endopeptidases

^aMolecular Biology II, Center of Medical Biotechnology (ZMB)/Center for Nanointegration Duisburg-Essen (CENIDE), University of Duisburg-Essen, Universitätsstrasse 5, 45141 Essen, Germany. E-mail: shirley.knauer@uni-due.de

^bOrganic Chemistry, Center for Nanointegration Duisburg-Essen (CENIDE), University of Duisburg-Essen, Universitätsstrasse 7, 45141 Essen, Germany. E-mail: jochen.niemeyer@uni-due.de

^cStructural and Medicinal Biochemistry, Center for Medical Biotechnology (ZMB), University of Duisburg-Essen, Universitätsstrasse 5, 45141 Essen, Germany

^dBioinformatics and Computational Biophysics, Center for Medical Biotechnology (ZMB), University of Duisburg-Essen, Universitätsstrasse 5, 45141 Essen, Germany

^eMolecular and Cellular Oncology/ENT, University Medical Center Mainz (UMM), Langenbeckstrasse 1, 55101 Mainz, Germany

† Electronic supplementary information (ESI) available: Chemical and biological assays, computational studies and microscopy, supporting figures and tables. See DOI: <https://doi.org/10.1039/d2ra06019a>



α interaction and correlated with both higher binding affinity and inhibition of proteolytic activity. As such, highest binding affinities ($K_D = 60 \mu\text{M}$) and most effective interference with Importin α interaction as well as proteolytic activity was revealed for the pentavalent ligand system. Notably, molecular weights of the largest multivalent tweezer systems are already in the low kDa range and approach the size of polypeptides (20–40 mers).

This study however for the first time characterized multivalent phosphates as a potent class of ligands suited to target Taspase 1. Hence, based on this knowledge and the available structural information,^{26,36} we hypothesized that also other compounds with multiple anionic binding sites might in general be suited to rationally address the NLS-loop in Taspase 1. Desirably, such ligands should feature a smaller molecular weight, making them most likely not only synthetically more readily available, but supposedly also cell permeable. In addition, an increased rigidity of such small molecules compared to the multivalent tweezer system should still enable the restriction of the enzyme's molecular motion and thus to inhibit its catalytic activity (Fig. 1). Likewise, such chemical structures should be indeed prone to function as 'dual inhibitors', enabling to address two independent enzyme functions by binding to a single site.

Results and discussion

Synthesis and characterization of NLS-targeting ligands

For applications in chemosensing and organocatalysis, we have recently established a library of structurally related, low molecular weight bis- and trisphosphates.^{57–60} These organic, multivalent ligands are based on rigid aromatic backbones, which allows a control of the relative positioning of the anionic phosphate groups in space, possibly offering a way to influence the strength and selectivity of binding to the NLS domain comprising clusters of lysine and arginine residues (Fig. 1B) by systematic structural variations. Initially, three chiral bis- and triphosphates allowing the selective recognition of cations were synthesized based on the covalent linkage of 1,1'-binaphthylphosphoric acids (**1d/e/f**, see ESI, Fig. S3,† numbering of all ligands based on earlier publications).⁶⁰ Here, the bisphosphoric acid ligands **1e** and in particular **1d** allowed for a highly stereoselective binding of D-lysine.⁶⁰ Subsequently, our library of linked aromatic phosphoric acid diesters was complemented by a series of related monoesters (**11d/e/f**, Fig. 2, and see ESI, Fig. S3†).⁶⁰ In contrast to the diesters, the latter class of ligands could be successfully utilized as chemosensors for different amino sugars.^{57–59} They partially even revealed selective binding to certain sugar species, but have not yet been tested for their interaction with cationic protein-residues. Notably, all of these hosts ligands are synthetically readily available also on gram-scale which makes them exceptionally attractive for a broad range of potential biomedical applications.

Importantly, the bis/trisphosphate-diester **1d/e/f** can feature two or three negative charges on their phosphate groups, while the bis/trisphosphate-monoesters **11d/e/f** can even possess four or six negative charges, respectively. This




Fig. 2 Chemical structures of phosphate-based ligands (*all-R*)-**1d/e/f** and (*all-R*)-**11d/e/f**. The ligands were exclusively used as the (*R,R*)- and (*R,R,R*)-isomers respectively (no further stereodescriptors are given in the text).

potentially enables strong and selective binding to the positively charged lysine and arginine residues constituting the NLS domain.

In terms of photophysical properties, ligands **1d/e/f** and **11d/e/f** show blue fluorescence with emission wavelengths in the range of $\lambda_{em} = 450\text{--}470 \text{ nm}$ ($\lambda_{exc} = 380/405 \text{ nm}$, see Fig. S5†). Although quantum yields of these compounds are similar ($\Phi = 0.21\text{--}0.70$ at $\lambda_{exc} = 305 \text{ nm}$, see Table S2†), the strongest relative fluorescence intensities are found for **1d** and **11d** due to their stronger UV/vis-absorption at 380/405 nm (in comparison to **1e/f** and **11e/f**) (see Fig. S5†). This enables their exploitation as fluorescence-based chemosensors *in vitro* as well as *in vivo*.^{61,62}

Screening of the library for promising candidates

Consequently, we first applied a customized biochemical pull-down assay employing pure, recombinantly expressed proteins (see ESI, Fig. S9†) to analyze the effects of our small focused library of phosphate-based ligands on the binding of Taspase 1 to Importin α (see ESI for details, Fig. S10 and S11†).^{35,54} As this interaction crucially relies on the basic NLS clusters present in the Taspase 1 loop, the assay serves as a reliable and direct readout to support our ligand binding



hypothesis. Briefly, Importin α is expressed with an N-terminal glutathione S-transferase (GST) tag and immobilized on a sepharose column. Subsequently, binding of Taspase 1-His in the presence or absence of ligands allows to quantify the compounds inhibitory potential (see ESI, Fig. S11[†]). Of note, since wildtype Taspase 1 partially undergoes autoproteolysis during protein purification, we here used a proteolytically inactive Taspase 1 mutant (D233A/T234A) ensuring a stable concentration of the proenzyme for robust and reliable detection.

With this assay, we could identify **11d** as the most promising candidate to perturb the Taspase 1/Importin α interaction at a concentration of 100 μM when compared to the other ligands. Notably, the chemical properties of **1f** resulted in a strong interference with the chemiluminescent protein detection (data not shown). Thus, this ligand was omitted to allow a robust evaluation of the ligands' performance. Based on our results, and to ensure an optimal comparability, we decided to continue our studies with the sub-library **11d/e/f**. As a perfect set of structurally related ligands, the paramount performance of **11d** would thus be nicely accompanied by a moderately active compound (**11e**) and a presumably inactive control (**11f**).

Molecular modelling of NLS-targeting ligands

To now manifest our assumption that in particular biphosphate ligand **11d** might allow the molecular recognition of Taspase 1's NLS domain we next employed *in silico* molecular modelling on ligands **11d/e/f** (Fig. 2, and see ESI[†]). Using a recently developed tool for scanning the surface of proteins with fragments of large ligands called *Epitopsy* followed by a Simulated Annealing Monte Carlo Simulation (SAMC), we identified the energetically most favorable binding sites for these ligands on the surface of Taspase 1. Therefore, we made use of a bead-spring model where each respective group is represented by one bead. Accordingly, ligands **11d** and **11e** are substituted by 5, and ligands **11f** by 7 beads. Spring constants and equilibrium lengths between the beads are the same for all ligands, and so were all other simulation parameters. Notably, the only difference between ligands **11d** and **11e** is the angles that are not considered in the bead-spring model. As such, our model




Fig. 3 SAMC simulations predict the energetically most favourable binding site of **11d** on Taspase 1, with the ligand represented as a bead-spring model. The magnified image (green circle) is the atomistic view of **11d** with each colour indicating the respective group represented by one bead. Blue, bipartite NLS; red square: active site.

cannot distinguish between these structures, and simulation results are the same for both biphosphate ligands. However, SAMC simulations indeed located the energetically most favorable binding site of **11d/e** at the loop optimally contacting the basic NLS residues (Fig. 3; see ESI, Fig. S6 and S7[†]). Interestingly, also the minimum energy conformation of **11f** was found near the loop, although seemingly more displaced towards the proximal turn region with less contact to the helix (Fig. S8[†]). From the modelling data, biphosphate ligands might allow a tighter and more stable association with the loop and thus reveal a higher inhibitory potential.

11d is a potent inhibitor of the Taspase 1/Importin α interaction

To subsequently substantiate our findings from the molecular simulations, we again made use of our customized biochemical pull-down assay (see ESI, Fig. S10 and S11[†]) employing pure recombinant proteins (see ESI, Fig. S9[†]) to analyze the ligands' effects on the Taspase 1/Importin α interaction (Fig. 4, and see ESI for details[†]).^{35,54}

As shown in Fig. 4, **11d** could indeed be verified as the most potent inhibitor of the Taspase 1/Importin α interaction, reducing the amount of bound Taspase 1 by more than 93% at a concentration of 100 μM (Fig. 4). In contrast, compound **11e** was less effective (reduction by 50%), and the trivalent derivative **11f** did not reduce binding, thereby again confirming the results of our previous library screen (see ESI Fig. S12[†]). Therefore, we now finally decided to merely focus on **11d** as the most promising candidate for further characterization. To increase our resolution, we also performed pull-down assays with low micromolar concentrations of **11d** (2–8 μM ; Fig. 5A). Notably, **11d** significantly interfered with the Taspase 1/Importin α interaction already at 6 μM , and densitometric quantification of the respective immunoblots resulted in an IC_{50} of $6.10 \pm 0.27 \mu\text{M}$ (Fig. 5, see ESI, Fig. S14[†]). As an important control, the binding of GST-Importin α to the matrix was not affected by the ligand itself (see ESI, Fig. S13[†]).




Fig. 4 The interaction between Taspase 1 and Importin α is effectively disrupted by **11d**. (A) Pull-down assay with 100 μM of indicated ligands. Controls: Taspase 1-His (C1) or GST-Importin α (C2) alone were added to the column, and a DMSO-treated sample served as reference. (B) Densitometric quantification of pull-down assays, comprising the mean of three replicates \pm standard deviation (* $p < 0.05$, ** $p < 0.01$) compared to the DMSO control.






Fig. 5 **11d** efficiently prevents Taspase 1/Importin α interaction. (A) Pull-down assay with increasing concentrations of **11d** (2–8 μM). Controls: Taspase 1-His (C1) or GST-Importin α (C2) alone were added to the column; a DMSO-treated sample served as reference. (B) Densitometric quantification of pull-down assays reveals a half maximal inhibitory concentration of **11d** in the low micromolar range ($\text{IC}_{50} = 6.10 \mu\text{M} \pm 0.27 \mu\text{M}$). Quantification comprises the mean of three replicates \pm standard deviation (see ESI \dagger).

11d is a Taspase 1 loop binder

Our assumption that **11d** might specifically recognize the NLS domain was comprehensively supported by independent evidence: first, to prove the direct binding of **11d** to the protease experimentally, we used a quantitative fluorescence anisotropy assay. Here, recombinant full-length Taspase 1 was titrated to a constant concentration of the fluorescent ligand **11d**, which revealed a strong binding KD in the nanomolar range ($\text{KD} = 300 \pm 50 \text{ nM}$) (see ESI, Fig. S15 \dagger). Second, to further narrow down **11d**'s binding site, we coupled an N-terminal FAM-label to the NLS peptide loop (aa S181-D233) and performed fluorescence titration experiments. A decrease in fluorescence due to compound binding in close proximity to the label was observed ($\text{KD} = 3 \mu\text{M}$), in contrast to the negative control (FAM-label without peptide; see ESI, Fig. S16 \dagger). Third, NMR titration experiments with the isolated Taspase 1 NLS loop and **11d** revealed a change in relative signal intensities and thus additionally verified binding of **11d** to the NLS loop (see ESI, Fig. S17 \dagger).

Dual activity: 11d also inhibits Taspase 1's proteolytic function

We convincingly demonstrated that **11d** efficiently disrupts the Taspase 1/Importin α interaction (activity #1). Next, we tested our hypothesis that binding of **11d** to the loop region also affects the protease's proteolytic activity. To verify this second, independent effect (activity #2), we first employed a biochemical colorimetric cleavage assay using a recombinant fusion protein harbouring the MLL CS2 substrate cleavage site (Fig. 6, and see SI \dagger). As shown in Fig. 6A, addition of recombinant, proteolytically active Taspase 1 resulted in substrate cleavage that was efficiently inhibited by **11d** in a concentration-dependent manner (Fig. 6A). **11d** turned out to act as a highly potent inhibitor, already preventing cleavage at low micromolar concentrations as revealed by densitometric quantification ($\text{IC}_{50} \approx 2 \mu\text{M}$) (Fig. 6B).




Fig. 6 **11d** interferes with Taspase 1's proteolytic activity. (A) Cleavage of a recombinant substrate by Taspase 1 was assessed *via* SDS-PAGE and Coomassie staining after 90 min reaction time in absence and presence of **11d** (0.1–10 μM). Inhibition of proteolysis by **11d** was already evident at a concentration between 3 and 4 μM . A DMSO-treated sample served as reference. (B) Densitometric quantification of the uncleaved substrate (asterisk) and its cleaved products (arrows) verifies an IC_{50} in the lower micromolar range ($1.96 \pm 0.14 \mu\text{M}$).

To independently substantiate the dual inhibition activity, we additionally established a FRET-based assay. Here, a MLL CS2 cleavage site peptide was coupled to a quencher and a fluorophore.

Addition of proteolytically active, wild-type Taspase 1 resulted in cleavage and an increase in fluorescence (see ESI, Fig. S18 \dagger). In contrast, **11d** efficiently inhibited Taspase 1's proteolytic activity, indicated by a lack of signal increment. To next mimic a cellular environment in which other proteins may act as (potent) competitors, we added different amounts of cancer cell lysates to our assay. Notably, **11d** was still able to reduce Taspase 1's proteolytic activity to 50% even in the presence of a 30-fold excess of cellular proteins, underlining **11d**'s specificity and setting the stage for subsequent assays in living tumour cells.

Dual inhibition *in vivo*: 11d suppresses Taspase 1 function also in living cancer cells

An absolute requirement for an inhibitor's *in vivo* activity and potential therapeutic/clinical relevance in drug development is its access to the relevant target protein inside disease cells. Notably, most suggested Taspase 1 inhibitors reported to date failed to convincingly take this key hurdle.^{16,23,63} Hence, we first controlled the uptake of **11d** in live cells utilizing its auto-fluorescence. Fluorescence microscopy confirmed that **11d** efficiently entered Taspase 1 expressing carcinoma cells already 1 h following incubation. Notably, to substantiate the internalization of the compound, we included a fluorescent outer plasma membrane staining following fixation (Fig. 7), and in addition generated maximum projection images from stacks (see ESI, Fig. S19 \dagger). Hereby, we could confirm that the compound was completely surrounded by the outer plasma membrane following successful intracellular uptake. Although no ample proof, the mainly homogeneous cytoplasmic distribution of **11d** indicates for its intracellular bioavailability.

Next, we tested the inhibitory activity of **11d** in tumor cells using a cell-based *in vivo* biosensor assay. Our biosensor fusion






Fig. 7 **11d** enters living tumour cells. Cells were incubated with 50 μM **11d** for 1 h, and the plasma membrane was stained with CellBrite® (green). Confocal microscopy detects the blue-fluorescent compound **11d** inside HeLa Kyoto cells. Scale bars, 30 μm .

protein (TASP_{BS}) consists of a red fluorescent (mCherry) protein coupled to the simian virus 40 (SV40) nuclear localization sequence (NLS) and a dominant, strong nuclear export signal (NES) from the human immunodeficiency virus 1 (HIV-1) Rev protein separated by the *bona fide* MLL CS2 Taspase 1 cleavage site (Fig. 8A). As illustrated, TASP_{BS} shuttles continuously between the nucleus and the cytoplasm. As the NES is dominant over the NLS, the uncleaved biosensor's steady-state localization is predominantly cytoplasmic. Cleavage by Taspase 1 however results in the loss of the NES, thereby triggering TASP_{BS}' nuclear accumulation (Fig. 8A). Experimentally, the red fluorescent TASP_{BS} accumulated in the nucleus in Taspase 1 co-expressing HeLa Kyoto cells (Fig. 8B, lower panel). In contrast, treatment with **11d** effectively inhibited Taspase 1-mediated biosensor cleavage (>10-fold; Fig. 8C and D) as demonstrated by TASP_{BS}'s exclusive cytoplasmic localization in **11d**-treated cells (Fig. 8B, upper panel, and Fig. 8C).

Results were additionally quantified by randomized image quantification (see ESI, Fig. S20 and Table S5†), characterizing **11d** as a unique highly potent cell-permeable inhibitor of this protease. To exclude the formal possibility that **11d** unspecifically interferes with the import of the biosensor itself, Taspase 1-expressing HeLa Kyoto cells were transfected with TASP_{BS} and successively treated with **11d** in combination with the nuclear export inhibitor LMB.⁶⁴ Blocking export allowed nuclear import and thus nuclear accumulation of the biosensor even in the presence of **11d**, excluding an unspecific inhibition with the TASP_{BS} NLS or import in general (see ESI, Fig. S21†). Although our cell studies did not reveal any changes in cellular morphology, we additionally tested ligand **11d** in a cell viability assay where it showed no toxicity (see ESI, Fig. S22†).

Clearly, future work needs to thoroughly investigate **11d**'s effectivity and bioavailability in tumour models with improved complexity. Although compounds such as **11d** have a relatively low solubility in aqueous environments, our data obtained in biochemical as well as cancer cell culture condition clearly demonstrate their applicability. Nevertheless, one may seek to

improve their solubility by additional chemical modifications, such as the introduction of peripheral solubilizing groups or a downsizing of the aromatic backbones (whilst maintaining the distance between the two phosphate groups). Moreover, the rational engineering of pharmacophores and delivery by nano-based drug formulations might be explored.^{32,65} However, convincing Taspase 1 specific small animal tumour models are




Fig. 8 **11d** interferes with Taspase 1 proteolytic activity in living cancer cells. (A) Modular structure of the autofluorescent Taspase 1-biosensor (TASP_{BS}). Taspase 1-mediated cleavage results in the biosensor's nuclear accumulation. (B) Confocal microscopy of TASP_{BS}-expressing HeLa Kyoto cells, treated with 50 μM **11d** for 24 h (upper panel) or DMSO control (lower panel). Scale bars, 50 μm ; frames indicate representative close-ups. (C) Quantification of TASP_{BS}'s intracellular localization (see ESI, Table S5†). Microscopic images were acquired in at least 100 cells and randomized for localization assignment (see ESI, Table S5†). Results are the mean of triplicates \pm standard deviation (* p < 0.5; *** p < 0.001). (D) Inhibitory effect of **11d** as represented by the ratio of the mean percentage of cells in the category 'Predominantly cytoplasm' (P_C) vs. 'Predominately nucleus' (P_N) normalized to 1 for the DMSO control.



not yet available.²³ Thus, we do not wish to postulate that **11d** is 'ready' for clinical translation, which may be considered a potential limitation of our work. We are also aware that our approach may not be generalized to any disease-relevant protein as it relies on the surface presentation of relevant basic amino acids in a distinct orientation of a bipartite NLS on a flexible loop structure. Although the monopartite SV40 NLS present in our biosensor was not affected by **11d** (see ESI, Fig. S21†), a plethora of NLSs have been identified in many cancer-/disease-relevant proteins, such as p53, NPM, TFIIA, or the superfamily of nuclear receptors, with the vast majority classified as monopartite signals.^{19,30,66–68}

However, recent studies revealed that the traditional definition of bipartite NLSs might be too restrictive and linker length can vary within a broader range.⁶⁹ As such, extension of the surface-exposed, importin-interacting amino acid residues of NLSs initially classified as monopartite might render them amenable to analogous interference strategies.

Moreover, as enzymatic/functional relevant domains are often localized in close proximity, we feel that our 'proof of principle' study is not limited to Taspase 1 but similar approaches might be successfully translated to other targets.

Conclusions

Based on a comprehensive *in silico*, analytical, biochemical, and live cell approach, we demonstrated that the bisphosphate ligand **11d** is a potent dual active inhibitor for Taspase 1. Our conclusion is based on independent experimental evidence: for one, molecular modeling combined with NMR and binding experiments confirmed **11d**'s selectivity for the basic cluster (²²⁰KKRR²²³) in Taspase 1's NLS. Second, **11d**'s high NLS binding affinity prevented Taspase 1's interaction with Importin α interfering with nuclear entry and protease activation (activity #1). Third, biochemical cell-free assays showed that **11d** additionally affected the protease's catalytic cleavage function, most likely by restricting the molecular flexibility of the bound loop (activity #2; Fig. 1). Fourth, **11d** efficiently inhibited Taspase 1 also in cancer-relevant cell models.

We demonstrate that by binding to a single site, compound **11d** simultaneously inhibits Taspase 1's protein-protein-interaction-based activation and its enzymatic function also in a physiological environment. This study thereby introduces the concept that dual activity inhibition through a single ligand by binding to a single site is possible with high efficiency also inside cells. Hence, 'targeting two for the price of one' by addressing multiple independent functions in a disease-relevant cellular protein *via* a single inhibitor should no longer be considered a 'too ambitious' goal, thereby stimulating the design of similar inhibitors for other targets.

Author contributions

AH purified the proteins and performed all biological experiments. RS synthesized and purified the compounds. CB performed the NMR experiments and interpreted the data together with PB. NR carried out the computational studies and analyzed

the results together with DH. SK and JN designed the study and supervised the experiments. AH assembled the figures and wrote the manuscript together with SK, RHS and JN. All authors have given approval to the final version of the manuscript.

Conflicts of interest

There are no conflicts to declare.

Acknowledgements

The authors acknowledge the CRC 1093 funded by the 'Deutsche Forschungsgemeinschaft'. We acknowledge the use of the imaging equipment and the support of the "Imaging Center Campus Essen" (ICCE). Instrument Leica TCS SP8X FALCON was obtained through DFG funding (Major Research Instrumentation Program, INST 20876/294-1 FUGG).

References

- 1 K. Baby, S. Maity, C. H. Mehta, A. Suresh, U. Y. Nayak and Y. Nayak, *Eur. J. Pharmacol.*, 2021, **896**, 173922.
- 2 T. Stankovic, J. Dinic, A. Podolski-Renic, L. Musso, S. S. Buric, S. Dallavalle and M. Pesic, *Curr. Med. Chem.*, 2019, **26**, 6074–6106.
- 3 M. Szumilak, A. Wiktorowska-Owczarek and A. Stanczak, *Molecules*, 2021, **26**, 2601.
- 4 A. Flemming, *Nat. Rev. Drug Discovery*, 2016, **15**, 455.
- 5 C. Harrison, *Nat. Rev. Drug Discovery*, 2010, **9**, 271.
- 6 P. Cohen, D. Cross and P. A. Jänne, *Nat. Rev. Drug Discovery*, 2021, **20**, 551–569.
- 7 D. Romero, *Nat. Rev. Clin. Oncol.*, 2017, **14**, 328.
- 8 M. Brazil, *Nat. Rev. Drug Discovery*, 2003, **2**, 170–171.
- 9 J. Sohn, T. I. Kim, Y. H. Yoon, J. Y. Kim and S. Y. Kim, *J. Clin. Invest.*, 2003, **111**, 121–128.
- 10 C. Vallet, D. Aschmann, C. Beuck, M. Killa, A. Meiners, M. Mertel, M. Ehlers, P. Bayer, C. Schmuck, M. Giese and S. K. Knauer, *Angew. Chem., Int. Ed.*, 2020, **59**, 5567–5571.
- 11 A. Meiners, S. Backer, I. Hadrovic, C. Heid, C. Beuck, Y. B. Ruiz-Blanco, J. Mieres-Perez, M. Porschke, J. N. Grad, C. Vallet, D. Hoffmann, P. Bayer, E. Sanchez-Garcia, T. Schrader and S. K. Knauer, *Nat. Commun.*, 2021, **12**, 1505.
- 12 D. A. Uhlenheuer, K. Petkau and L. Brunsveld, *Chem. Soc. Rev.*, 2010, **39**, 2817–2826.
- 13 S. K. Knauer, V. Fetz, J. Rabenstein, S. Friedl, B. Hofmann, S. Sabiani, E. Schröder, L. Kunst, E. Proschak, E. Thines, T. Kindler, G. Schneider, R. Marschalek, R. H. Stauber and C. Bier, *PLoS One*, 2011, **6**, e18253.
- 14 A. Höing, A. Zimmermann, L. Moews, M. Killa, M. Heimann, A. Hensel, J. Voskuhl and S. K. Knauer, *ChemMedChem*, 2022, **17**, e202100640.
- 15 A. Gribko, A. Hahlbrock, S. Strieth, S. Becker, J. Hagemann, M. Deichelbohrer, A. Hildebrandt, N. Habtemichael and D. Wunsch, *Sci. Rep.*, 2017, **7**, 14937, DOI: [10.1038/s41598-017-14814-x](https://doi.org/10.1038/s41598-017-14814-x).



- 16 J. v. d. Boom, M. Mamić, D. Baccelliere, S. Zweerink, F. Kaschani, S. Knauer, P. Bayer and M. Kaiser, *ChemBioChem*, 2014, **15**, 2233–2237.
- 17 C. Bier, S. K. Knauer, D. Wünsch, L. Kunst, S. Scheiding, M. Kaiser, C. Ottmann, O. H. Krämer and R. H. Stauber, *FASEB J.*, 2012, **26**, 3421–3429.
- 18 C. Bier, S. K. Knauer, A. Klaphthor, A. Schweitzer, A. Rezik, O. H. Krämer, R. Marschalek and R. H. Stauber, *J. Biol. Chem.*, 2011, **286**, 3007–3017.
- 19 C. Bier, S. K. Knauer, D. Docter, G. Schneider, O. H. Kramer and R. H. Stauber, *Traffic*, 2011, **12**, 703–714.
- 20 C. Bier, R. Hecht, L. Kunst, S. Scheiding, D. Wunsch, D. Goesswein, G. Schneider, O. H. Kramer, S. K. Knauer and R. H. Stauber, *PLoS One*, 2012, **7**, e34142.
- 21 C. López-Otín and J. S. Bond, *J. Biol. Chem.*, 2008, **283**, 30433–30437.
- 22 J. S. Bond, *J. Biol. Chem.*, 2019, **294**, 1643–1651.
- 23 D. Wünsch, A. Hahlbrock, S. Jung, T. Schirmeister, J. v. d. Boom, O. Schilling, S. K. Knauer and R. H. Stauber, *Oncogene*, 2016, **35**, 3351–3364.
- 24 D. Y. Chen, H. Liu, S. Takeda, H.-C. Tu, S. Sasagawa, B. A. van Tine, D. Lu, E. H.-Y. Cheng and J. J.-D. Hsieh, *Cancer Res.*, 2010, **70**, 5358–5367.
- 25 J. J.-D. Hsieh, E. H.-Y. Cheng and S. J. Korsmeyer, *Cell*, 2003, **115**, 293–303.
- 26 J. A. Khan, B. M. Dunn and L. Tong, *Structure*, 2005, **13**, 1443–1452.
- 27 S. Takeda, D. Y. Chen, T. D. Westergard, J. K. Fisher, J. A. Rubens, S. Sasagawa, J. T. Kan, S. J. Korsmeyer, E. H.-Y. Cheng and J. J.-D. Hsieh, *Genes Dev.*, 2006, **20**, 2397–2409.
- 28 H. Zhou, S. Spicuglia, J. J.-D. Hsieh, D. J. Mitsiou, T. Høiby, G. J. C. Veenstra, S. J. Korsmeyer and H. G. Stunnenberg, *Mol. Cell. Biol.*, 2006, **26**, 2728–2735.
- 29 S. Takeda, S. Sasagawa, T. Oyama, A. C. Searleman, T. D. Westergard, E. H. Cheng and J. J. Hsieh, *J. Clin. Invest.*, 2015, **125**, 1203–1214.
- 30 C. Schrenk, V. Fetz, C. Vallet, C. Heiselmayer, E. Schroder, A. Hensel, A. Hahlbrock, D. Wunsch, D. Goesswein, C. Bier, N. Habtemichael, G. Schneider, R. H. Stauber and S. K. Knauer, *J. Mol. Cell Biol.*, 2018, **10**, 33–47.
- 31 D. Y. Chen, Y. Lee, B. A. van Tine, A. C. Searleman, T. D. Westergard, H. Liu, H.-C. Tu, S. Takeda, Y. Dong, D. R. Piwnica-Worms, K. J. Oh, S. J. Korsmeyer, A. Hermone, R. Gussio, R. H. Shoemaker, E. H.-Y. Cheng and J. J.-D. Hsieh, *Cancer Res.*, 2012, **72**, 736–746.
- 32 S. Siemer, T. A. Bauer, P. Scholz, C. Breder, F. Fenaroli, G. Harms, D. Dietrich, J. Dietrich, C. Rosenauer, M. Barz, S. Becker, S. Strieth, C. Reinhardt, T. Fauth, J. Hagemann and R. H. Stauber, *ACS Nano*, 2021, **15**, 18541–18556.
- 33 S. Siemer, T. Fauth, P. Scholz, Y. Al-Zamel, A. Khamis, D. Gül, L. Freudelsperger, B. Wollenberg, S. Becker, R. H. Stauber and J. Hagemann, *Cancers*, 2021, **13**, 4831, DOI: [10.3390/cancers13194831](https://doi.org/10.3390/cancers13194831).
- 34 J. van den Boom, A. Hensel, F. Trusch, A. Matena, S. Siemer, D. Guel, D. Docter, A. Höing, P. Bayer, R. H. Stauber and S. K. Knauer, *Nanoscale*, 2020, **12**, 19093–19103.
- 35 P. Pasch, A. Höing, S. Ueclue, M. Killa, J. Voskuhl, S. K. Knauer and L. Hartmann, *Chem. Commun.*, 2021, **57**, 3091–3094.
- 36 J. van den Boom, F. Trusch, L. Hoppstock, C. Beuck and P. Bayer, *PLoS One*, 2016, **11**, e0151431.
- 37 N. Nagaratnam, S. L. Delker, R. Jernigan, T. E. Edwards, J. Snider, D. Thifault, D. Williams, B. L. Nannenga, M. Stofega, L. Sambucetti, J. J. Hsieh, A. J. Flint, P. Fromme and J. M. Martin-Garcia, *Structure*, 2021, **29**, 873–885.
- 38 M. Giese, J. Niemeyer and J. Voskuhl, *ChemPlusChem*, 2020, **85**, 985–997.
- 39 D. Aschmann, C. Vallet, S. K. Tripathi, Y. B. Ruiz-Blanco, M. Brabender, C. Schmuck, E. Sanchez-Garcia, S. K. Knauer and M. Giese, *ChemBioChem*, 2022, **23**, e202100618.
- 40 L. Bartsch, M. Bartel, A. Gigante, J. Iglesias-Fernández, Y. B. Ruiz-Blanco, C. Beuck, J. Briels, N. Toetsch, P. Bayer, E. Sanchez-Garcia, C. Ottmann and C. Schmuck, *ChemBioChem*, 2019, **20**, 2921–2926.
- 41 A. Gigante, E. Sijbesma, P. A. Sanchez-Murcia, X. Hu, D. Bier, S. Backer, S. Knauer, F. Gago, C. Ottmann and C. Schmuck, *Angew. Chem., Int. Ed.*, 2020, **59**, 5284–5287.
- 42 D. Maity, A. Gigante, P. A. Sanchez-Murcia, E. Sijbesma, M. Li, D. Bier, S. Mosel, S. Knauer, C. Ottmann and C. Schmuck, *Org. Biomol. Chem.*, 2019, **17**, 4359–4363.
- 43 N. Raffieiolhosseini, M. Killa, T. Neumann, N. Tötsch, J.-N. Grad, A. Höing, T. Dirksmeyer, J. Niemeyer, C. Ottmann, S. K. Knauer, M. Giese, J. Voskuhl and D. Hoffmann, *Beilstein J. Org. Chem.*, 2022, **18**, 1322–1331.
- 44 T. Dirksmeyer, P. Stahl, C. Vallet, S. Knauer, M. Giese, C. Schmuck and C. Hirschhauser, *Chem. –Eur. J.*, 2022, **28**, e202104618.
- 45 X. Y. Hu, M. Ehlers, T. Wang, E. Zellermann, S. Mosel, H. Jiang, J. E. Ostwaldt, S. K. Knauer, L. Wang and C. Schmuck, *Chem. –Eur. J.*, 2018, **24**, 9754–9759.
- 46 P. Jana, K. Samanta, S. Bäcker, E. Zellermann, S. Knauer and C. Schmuck, *Angew. Chem., Int. Ed.*, 2017, **56**, 8083–8088.
- 47 H. Jiang, X. Y. Hu, S. Mosel, S. K. Knauer, C. Hirschhauser and C. Schmuck, *ChemBioChem*, 2019, **20**, 1410–1416.
- 48 S. Junghanel, S. Karczewski, S. Backer, S. K. Knauer and C. Schmuck, *ChemBioChem*, 2017, **18**, 2268–2279.
- 49 H. Y. Kuchelmeister, A. Gutschmidt, S. Tillmann, S. Knauer and C. Schmuck, *Chem. Sci.*, 2012, **3**, 996–1002.
- 50 H. Y. Kuchelmeister, S. Karczewski, A. Gutschmidt, S. Knauer and C. Schmuck, *Angew. Chem., Int. Ed.*, 2013, **52**, 14016–14020.
- 51 M. Li, M. Ehlers, S. Schlesiger, E. Zellermann, S. K. Knauer and C. Schmuck, *Angew. Chem., Int. Ed.*, 2016, **55**, 598–601.
- 52 M. Li, S. Schlesiger, S. K. Knauer and C. Schmuck, *Angew. Chem., Int. Ed.*, 2015, **54**, 2941–2944.
- 53 K. Samanta, P. Jana, S. Backer, S. Knauer and C. Schmuck, *Chem. Commun.*, 2016, **52**, 12446–12449.
- 54 A. Höing, A. Zimmermann, L. Moews, M. Killa, M. Heimann, A. Hensel, J. Voskuhl and S. K. Knauer, *ChemMedChem*, 2022, **17**, e202100640.



- 55 M. Fokkens, T. Schrader and F. G. Klarner, *J. Am. Chem. Soc.*, 2005, **127**, 14415–14421.
- 56 A. Höing, A. Kirupakaran, C. Beuck, M. Pörschke, F. C. Niemeyer, T. Seiler, L. Hartmann, P. Bayer, T. Schrader and S. K. Knauer, *Biomacromolecules*, 2022, **23**, 4504–4518.
- 57 F. Octa-Smolín, R. Mitra, M. Thiele, C. G. Daniliuc, L. Stegemann, C. Strassert and J. Niemeyer, *Chem. –Eur. J.*, 2017, **23**, 10058–10067.
- 58 F. Octa-Smolín, F. van der Vight, R. Yadav, J. Bhangu, K. Soloviova, C. Wolper, C. G. Daniliuc, C. A. Strassert, H. Somnitz, G. Jansen and J. Niemeyer, *J. Org. Chem.*, 2018, **83**, 14568–14587.
- 59 R. Yadav, C. Kwamen and J. Niemeyer, *Isr. J. Chem.*, 2021, **61**, 231–233.
- 60 F. Octa-Smolín, M. Thiele, R. Yadav, A. Platzek, G. H. Clever and J. Niemeyer, *Org. Lett.*, 2018, **20**, 6153–6156.
- 61 M. K. Goshisht, G. K. Patra and N. Tripathi, *Mater. Adv.*, 2022, **3**, 2612–2669.
- 62 M. K. Goshisht and N. Tripathi, *J. Mat. Chem. C*, 2021, **9**, 9820–9850.
- 63 J. T. Lee, D. Y. Chen, Z. Yang, A. D. Ramos, J. J.-D. Hsieh and M. Bogyo, *Bioorg. Med. Chem. Lett.*, 2009, **19**, 5086–5090.
- 64 S. K. Knauer, W. Mann and R. H. Stauber, *Cell Cycle*, 2007, **6**, 518–521.
- 65 S. B. van der Meer, I. Hadrovic, A. Meiners, K. Loza, M. Heggen, S. K. Knauer, P. Bayer, T. Schrader, C. Beuck and M. Epple, *J. Phys. Chem. B*, 2021, **125**, 115–127.
- 66 A. Brandl, T. Wagner, K. M. Uhlig, S. K. Knauer, R. H. Stauber, F. Melchior, G. Schneider, T. Heinzl and O. H. Kramer, *J. Mol. Cell Biol.*, 2012, **4**, 284–293.
- 67 S. K. Knauer and R. H. Stauber, *Anal. Chem.*, 2005, **77**, 4815–4820.
- 68 A. Schweitzer, S. K. Knauer and R. H. Stauber, *Int. J. Cancer*, 2010, **126**, 801–809.
- 69 A. Lange, L. M. McLane, R. E. Mills, S. E. Devine and A. H. Corbett, *Traffic*, 2010, **11**, 311–323.

